David A. Siegel Neurocrine Biosciences Inc Transaction History

Two Sigma Advisers, LP

$41.3 Billion
Q3 2024

A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Two Sigma Advisers, LP holds 3,873 shares of NBIX stock, worth $524,481. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,873

Previous 34,773 88.86%

Holding current value

$524,481

Previous $4.79 Million 90.7%

% of portfolio

0.0%

Previous 0.01%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$114.58 - $153.15 $3.54 Million - $4.73 Million	-30,900 Reduced 88.86%	3,873 $445,000
Q2 2024 Aug 14, 2024	SELL	$130.86 - $143.19 $21 Million - $23 Million	-160,500 Reduced 82.19%	34,773 $4.79 Million
Q1 2024 May 15, 2024	SELL	$130.4 - $143.74 $1.98 Million - $2.18 Million	-15,200 Reduced 7.22%	195,273 $26.9 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $8.95 Million - $11.2 Million	-84,400 Reduced 28.62%	210,473 $27.7 Million
Q3 2023 Nov 14, 2023	SELL	$94.02 - $117.1 $24.4 Million - $30.4 Million	-259,400 Reduced 46.8%	294,873 $33.2 Million
Q2 2023 Aug 14, 2023	SELL	$89.53 - $104.87 $11.1 Million - $13.1 Million	-124,500 Reduced 18.34%	554,273 $52.3 Million
Q1 2023 May 15, 2023	SELL	$94.11 - $123.02 $4.13 Million - $5.4 Million	-43,900 Reduced 6.07%	678,773 $68.7 Million
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $13.6 Million - $16.2 Million	127,700 Added 21.46%	722,673 $86.3 Million
Q3 2022 Nov 14, 2022	BUY	$92.03 - $107.81 $12 Million - $14 Million	130,100 Added 27.99%	594,973 $63.2 Million
Q2 2022 Aug 15, 2022	SELL	$75.79 - $100.07 $12.4 Million - $16.4 Million	-163,900 Reduced 26.07%	464,873 $45.3 Million
Q1 2022 May 16, 2022	BUY	$72.45 - $94.81 $31.6 Million - $41.3 Million	435,600 Added 225.5%	628,773 $58.9 Million
Q4 2021 Feb 14, 2022	BUY	$79.65 - $106.22 $14 Million - $18.7 Million	176,300 Added 1044.86%	193,173 $16.5 Million
Q3 2021 Nov 15, 2021	BUY	$86.18 - $99.03 $1.45 Million - $1.67 Million	16,873 New	16,873 $1.62 Million
Q4 2020 Feb 16, 2021	SELL	$86.91 - $108.33 $37.4 Million - $46.6 Million	-430,299 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$96.16 - $135.15 $28.6 Million - $40.3 Million	-297,874 Reduced 40.91%	430,299 $41.4 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $808,355 - $1.24 Million	9,500 Added 1.32%	728,173 $88.8 Million
Q1 2020 May 15, 2020	SELL	$75.11 - $113.76 $8.45 Million - $12.8 Million	-112,500 Reduced 13.54%	718,673 $62.2 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $8.52 Million - $11.6 Million	98,200 Added 13.4%	831,173 $89.3 Million
Q3 2019 Nov 14, 2019	SELL	$83.82 - $101.5 $5.56 Million - $6.73 Million	-66,300 Reduced 8.3%	732,973 $66 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $3.06 Million - $3.87 Million	42,400 Added 5.6%	799,273 $67.5 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $9.32 Million - $12.3 Million	134,400 Added 21.59%	756,873 $66.7 Million
Q4 2018 Feb 14, 2019	BUY	$68.32 - $124.36 $5.26 Million - $9.58 Million	77,000 Added 14.12%	622,473 $44.5 Million
Q3 2018 Nov 14, 2018	BUY	$98.88 - $125.85 $23.6 Million - $30 Million	238,400 Added 77.64%	545,473 $67.1 Million
Q2 2018 Aug 14, 2018	BUY	$75.3 - $105.99 $20.9 Million - $29.4 Million	277,400 Added 934.86%	307,073 $30.2 Million
Q1 2018 May 15, 2018	BUY	$75.88 - $92.43 $1.41 Million - $1.72 Million	18,561 Added 167.04%	29,673 $2.46 Million
Q4 2017 Feb 14, 2018	BUY	$58.53 - $77.59 $650,385 - $862,180	11,112	11,112 $862,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track David A. Siegel's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.

Account